BLU News and Press, BELLUS Health Inc. From 10/25/20

Biotech Penny Stocks To Watch This Week Looking for top penny stocks to watch this week? You’re not alone. One of the hotter sectors to watch in the stock market today is biotech and healthcare. I’m not just saying that because coronavirus vaccines remain a hot button ...

BELLUS Health (BLU) gained 9.8% in after-hours trade last night after Point72 disclosed 7.9% stake or holding of 6.2M shares in the company. For further details see: BELLUS Health up 9.8% on Point72 stake disclosure

BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it ...

Common Shares Priced at US$2.25 per Share In connection with its previously announced public offering of common shares in Canada and the United States (the “Offering”), BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX a...

Gainers: [[APTX]] +89.3%. [[EMKR]] +14.8%. [[GNMK]] +8.9%. [[CCK]] +6.5%. [[NOK]] +3.8%.Losers: [[RAIL]] -9.6%. [[HXL]] -8.8%. [[BLU]] -6.9%. [[STLD]] -3.4%. [[TEO]] -3.3%. For further details see: APTX, GNMK, HXL and RAIL among after-hours movers

BELLUS Health (BLU) has filed a preliminary prospectus for base shelf offering associated with a planned public offering of common stock.Price, volume and terms have yet to be determined.Shares down 12% after hours. For further details see: Bellus Health under pressure on plan...

BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU), announced today the filing of a preliminary prospectus supplement (the “Supplement”) to its short form base shelf prospectus dated January 17, 2020 (the “Base Pr...

The following slide deck was published by BELLUS Health Inc. in conjunction with this Read more ...

- D ouble-blind, 4-week placebo controlled, parallel arm trial will evaluate the efficacy and safety of 3 doses of BLU-5937 in 280 patients with refractory chronic cough – - Trial to recruit patients with baseline cough count ≥25 coughs per hour -- RELIEF Phase 2 trial r...

BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto B...